# A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer

> **NCT03026803** · PHASE2 · TERMINATED · sponsor: **City of Hope Medical Center** · enrollment: 4 (actual)

## Conditions studied

- Liver Cancer
- Hepatocellular Cancer

## Interventions

- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT03026803
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-11
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Due to Sorafenib became first line treatment for HCC, the designed treatment became less competitive. The company Sanofi decided not to continue to support
- **Last updated:** 2017-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03026803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03026803, "A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03026803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*